After a successful feasibility study, Company expands into the high growth biopesticide sector with a funded research and development program to produce valuable natural ingredients using its precision fermentation platform Program expected to generate over $2 million in revenue in first year with guaranteed payments of over $1 million in 2024 Company now anticipates revenue of over $4 million in 2024 on existing programs SUNNYVALE, Calif. , Aug. 7, 2024 /PRNewswire/ - Willow Biosciences Inc.
(" Willow " or the " Company ") (TSX: WLLW) (OTCQB: CANSF ), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent, and sustainable ingredients, announces that it has signed a fully funded strain engineering program (the "Program" ) with an innovative Ag-Biotech company in the biopesticides sector. "This is truly an exciting partnership for Willow, as it not only comes with significant near-term research and development and future commercial milestone payments, but also extends our technology and capabilities into the high growth biopesticide sector," said Dr. Chris Savile , Willow's President & CEO.
"I am once again impressed with our team and technology platform for quickly demonstrating proof-of-concept and progressing to a full development partnership," continued Dr. Savile. On June 26, 2024 , the Company announced a feasibility program with an innovative Ag-Biotech company in the biopesticides sector.
Today, the Company announced tha.